In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Esperion, Again: Pfizer's First Spin-Out's Familiar Look

Executive Summary

This examination of Pfizer's first foray into spin-outs is a sidebar to "Can Out-Partnering Power Pfizer Over the "Second Cliff?"" Pfizer's Esperion spin-out hopes to pick up where it left off five years ago when Pfizer bought its first incarnation: developing HDL-raising therapies for CV disease.

You may also be interested in...

Conatus Acquires Idun's Assets

As it divests assets to restructure its research and development pipeline, Pfizer Inc. has found the best buyers are intimately familiar with what they're getting. In late July, the big pharma revealed it sold its Idun Pharmaceuticals Inc. subsidiary to Conatus Pharmaceuticals Inc., a startup founded by the same executives who led Idun prior to its nearly $300 million acquisition by Pfizer in 2005.

Corporate Venture Takes Center Stage

Corporate venture groups are poised to become one of the main sources of funding for early-stage biotechs thanks to the current economic climate. Even if corporate venture groups invest at the same levels as previous years, some industry veterans believe they could play a role in up to half of the early-stage financings this year, largely because the traditional sources of financing--the public market and venture capital groups flush with cash--have disappeared. And the new vigor of corporate venture offers big benefits to both small biotechs and Big Pharma.

The GSK/Pfizer HIV Venture: Another Sign of Change?

Pfizer and GSK inked an innovative deal to create a jointly owned company focused on HIV therapeutics. The marriage combines GSK's marketing muscle and a stable of established products with Pfizer's newer offerings. While it's unlikely the new venture will unseat rival Gilead as the top player in the HIV market, the deal could be a cash cow for both drug makers, especially if a spin-out ensues.

Related Content


Related Companies

Related Deals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts